Connect Biopharma Holdings Limited (CNTB)
CNTB Stock Price Chart
Explore Connect Biopharma Holdings Limited interactive price chart. Choose custom timeframes to analyze CNTB price movements and trends.
CNTB Company Profile
Discover essential business fundamentals and corporate details for Connect Biopharma Holdings Limited (CNTB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Mar 2021
Employees
62.00
Website
https://www.connectbiopharm.comCEO
Barry D. Quart
Description
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
CNTB Financial Timeline
Browse a chronological timeline of Connect Biopharma Holdings Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.32, while revenue estimate is $109.09k.
Earnings released on 12 May 2026
EPS came in at -$0.34 falling short of the estimated -$0.29 by -17.24%, while revenue for the quarter reached $24.42k .
Earnings released on 31 Mar 2026
EPS came in at -$0.27 surpassing the estimated -$0.30 by +10.00%.
Earnings released on 13 Aug 2025
EPS came in at -$0.23 falling short of the estimated -$0.22 by -4.55%, while revenue for the quarter reached $6.70k .
Earnings released on 31 Mar 2025
EPS came in at -$0.06 surpassing the estimated -$0.27 by +78.66%, while revenue for the quarter reached $261.88k .
Earnings released on 5 Sept 2024
EPS came in at $0.02 surpassing the estimated -$0.03 by +167.49%, while revenue for the quarter reached $3.32m , beating expectations by +12.54%.
Earnings released on 16 Apr 2024
EPS came in at -$0.07 falling short of the estimated -$0.03 by -131.68%.
Earnings released on 12 Sept 2023
EPS came in at -$0.08 surpassing the estimated -$6.92 by +98.89%.
Earnings released on 11 Apr 2023
EPS came in at -$0.15 surpassing the estimated -$3.58 by +95.80%.
Earnings released on 13 Sept 2022
EPS came in at -$0.16 surpassing the estimated -$5.28 by +96.93%.
Earnings released on 31 Mar 2022
EPS came in at -$0.17 surpassing the estimated -$4.38 by +96.22%.
Earnings released on 31 Aug 2021
EPS came in at -$0.48 surpassing the estimated -$2.36 by +79.66%.
CNTB Stock Performance
Access detailed CNTB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
